Gaps in beliefs and practice in dyslipidaemia management in Japan, Germany, Colombia and the Philippines:
insights from a web-based physician survey
Lipids in Health and Disease
Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR
Working Group on Visceral Obesity
Nature Reviews Endocrinology
Global Call to Action on Familial Hypercholesterolemia (FH)
JAMA Cardiology
The International Atherosclerosis Society together with the FH Foundation and the World Heart Federation announced today the publication of a Global Call to Action on familial hypercholesterolemia (FH), a vastly under-recognized and poorly managed public health concern, in JAMA Cardiology. Authored by a global panel of scientific experts, advocacy leaders, public health officials, advocacy leaders and individuals with FH from 40 countries, the report notes glaring gaps in screening and guideline-based care for FH, the most common cause of early and aggressive heart disease.
Here is the direct link to the paper (click here).
The success of the concrete and actionable recommendations we issue today will depend on the support from local and national societies, both scientific and civil, and from governments: this is why we are jointly addressing them as a global community now.
Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?
Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Visceral obesity as a risk factor for chronic societal disease is being recognized in a global consensus paper published in the prestigious medical journal
The Lancet Diabetes & Endocrinology
In 1983, using computed tomography, an imaging technique that was not used at the time for measuring body fat, a team of researchers from the Department of Internal Medicine at Osaka University led by Prof. Yuji Matsuzawa showed for the first time that there were substantial individual differences in the way human beings would store their body fat. Indeed, these Japanese researchers published fascinating images showing that despite similar body weights, some people would accumulate significant amounts of fat in their abdominal cavity, this fat being invisible from outside the body. They called that fat visceral fat and its excess, visceral obesity. In 1986, intrigued by these findings and at the very beginning of his career as an independent researcher at Université Laval, Prof. Jean-Pierre Després of the Department of Kinesiology at the Faculty of Medicine, launched with his colleagues a series of imaging studies where computed tomography would also be systematically used to assess the distribution of body fat (including abdominal fat) and its relationship to health outcomes. Soon enough, at the dawn of the 1990s, his team reported results that clearly showed the limits of the ideal body weight concept (body mass index) and the key importance of visceral fat (the fat located in the abdominal cavity) as a risk factor for chronic diseases such as cardiovascular diseases and type 2 diabetes. Read more
IAS and R3i Foundation publish new consensus on SPPARMα
The International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation announce a Joint Consensus Statement on Selective Peroxisome Proliferator Activated Receptor alpha Modulators (SPPARMα)
The International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation announce a Joint Consensus Statement on Selective Peroxisome Proliferator Activated Receptor alpha Modulators (SPPARMα)
Over 50 internationally recognized experts in lipid research and cardiovascular disease prevention make the case that the SPPARMα agonists represent a new therapeutic class distinct from fibrates.
Data supports the efficacy and safety of the first SPPARMα agonist pemafibrate in patients with atherogenic dyslipidemia, the combination of high triglycerides and a low plasma level of high-density lipoprotein cholesterol. This lipid profile is increasingly common as populations become fatter and more likely to develop diabetes. Fibrates do not reduce heart attacks and strokes against a background of statin treatment, and some have safety issues.
This Joint Consensus Statement is published by Cardiovascular Diabetology:
The Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator (SPPARMα) Paradigm: Conceptual Framework and Therapeutic Potential. A Consensus Statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
https://cardiab.biomedcentral.com/track/pdf/10.1186/s12933-019-0864-7
We are happy to inform that the excellent article has an outstanding number of the accesses: 2150 during only 3 weeks since publication (this metric reflects only the publisher website, maybe even more accesses could be expected from PubMed directly).
News from this IAS-R3i Consensus Panel Statement will be discussed at a Press Conference in Paris on September 1, 2019
A Review on “Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps” Raul D. Santos, Luca Valenti, Stefano Romeo just published in Atherosclerosis March 2019 Volume 282, Pages 110-120.
https://www.atherosclerosis-journal.com/article/S0021-9150(19)30053-X/fulltext
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is highly prevalent and includes a spectrum of abnormalities ranging from steatosis to cirrhosis. In this review, we address recent evidence and limitations of studies that evaluated the association of NAFLD with atherosclerotic cardiovascular disease. NAFLD is considered an ectopic fat deposit associated with metabolic (insulin resistance, hyperglycemia and dyslipidemia), inflammatory, coagulation and blood pressure disturbances. Prospective studies have associated NAFLD presence and severity, particularly steatohepatitis and fibrosis, with an increased risk of cardiovascular disease. However, these studies are limited by heterogeneity concerning NAFLD diagnostic criteria and disease severity stratification, as well as by the presence of confounding factors. In addition, genetic variants predisposing to NAFLD, such as the PNPLA3 I148M mutation, were not consistently associated with an increased risk of cardiovascular events. Therefore, currently, it is not possible to prove a causal relation between NAFLD and cardiovascular disease. Furthermore, there is presently no evidence that NAFLD diagnosis can be used as a tool to improve cardiovascular risk stratification and modify treatment. Specific treatments for NAFLD are being developed and must be tested prospectively in adequately designed trials to determine the potential of reducing both hepatic and cardiovascular diseases and to prove whether NAFLD is indeed a cause of atherosclerosis.
IAS SEVERE FH PANEL
IAS Consensus Statement “Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel”
The International Atherosclerosis Society (IAS) is proud to announce the publication on the definition of severe FH and the implications for clinical management in The Lancet Diabetes and Endocrinology. The IAS Severe FH Panel, made of 25 internationally renowned experts and chaired by Dr. Raul Santos, worked with the objective of characterizing the severe FH phenotype and made recommendations on how to stratify CVD risk and to whom to prescribe the novel lipid lowering treatments. These recommendations will contribute to improved daily clinical practice and better management of FH patients.
To download the full text, which is open access, please link to and register at SEVERE FH Article (Published online May 27, 2016).
For more information about The Lancet, please visit The Lancet Homepage at www.thelancet.com.
IAS Position Paper
IAS Position Paper: Global Recommendations for the Management of Dyslipidemia.
The International Atherosclerosis Society (IAS) here updates its recommendations on treatment of high level of blood cholesterol and dyslipidemia for the purpose of reducing risk for atherosclerotic cardiovascular disease (ASCVD). The Writing Panel, made of 15 internationally renowned experts and chaired by dr Scott M. Grundy, reviewed existing evidence-based recommendations and consolidated them into an overall set of recommendations. For comments and suggestions please write us at positionpaper@athero.org.
The Journal of Atherosclerosis and Thrombosis (JAT)
The Journal of Atherosclerosis and Thrombosis (JAT) is the official publication of the Japan Atherosclerosis Society and the Asian-Pacific Society of Atherosclerosis and Vascular Diseases. It is issued monthly and peer-reviewed. Contributions from non-members are also acceptable.
Manuscripts and other scientific correspondence should be addressed to:
The Japan Atherosclerosis Society (JAS)
Nichinai-kaikan B1, 3-28-8 Hongo
Bunkyo-ku, Tokyo 113-0033, Japan
Phone +81-3-5802-7711
e-mail: jas@j-athero.or.jp
“Instruction to Authors” is available from instructions.pdf
If you would like to submit, please access here.